Live Events

Sun Pharmaceutical Industries Limited announced it will present long-term efficacy and safety results for UNLOXCYT® (cosibelimab-ipdl) at the ESMO Congress on October 24, 2026. The data pertains to advanced cutaneous squamous cell carcinoma (aCSCC) from the pivotal CK-301-101 trial. UNLOXCYT®, approved by the FDA in 2024, is an immune checkpoint inhibitor for adults with mCSCC or laCSCC not eligible for curative surgery or radiation. The presentation will include updated results showing a significant percentage of patients achieving complete response (CR) and a consistent, favorable tolerability profile with low rates of high-grade immune-related adverse events (irAEs). Long-term follow-up data indicates durable disease control.

Gland Pharma Limited announced the conclusion of an unannounced USFDA inspection at its Dundigal formulation facility, which took place from October 12-23, 2026. The inspection resulted in four Form 483 Observations, which the company described as procedural. Gland Pharma will submit corrective and preventive actions to the USFDA within the stipulated period. The company stated that the observations are neither repeated nor related to data integrity. Further details are provided in Annexure A.

Cipla Ltd announced that its wholly owned subsidiary, InvaGen Pharmaceuticals Inc., located in Hauppauge, New York, underwent a routine current Good Manufacturing Practices (cGMP) inspection by the United States Food and Drug Administration (USFDA). The inspection, which took place from October 19th to October 22nd, 2026, concluded without any Form 483 observations. This outcome is positive for the subsidiary's operations and Cipla's overall compliance standing with US regulatory authorities.

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Estradiol and Levonorgestrel Transdermal System, 0.045 mg/0.015 mg per day. This product, used for treating menopausal symptoms and preventing osteoporosis, is designated as a Competitive Generic Therapy (CGT) by the USFDA. Consequently, Zydus is eligible for a 180-day exclusivity period upon its first commercial marketing. The drug had annual sales of approximately USD 45.7 million in the US. The product will be manufactured at Zydus's facility in Moraiya, Gujarat. This approval adds to Zydus's portfolio, bringing their total USFDA ANDA approvals to 458.

Sun Pharmaceutical Industries Limited announced that its drug UNLOXCYT® (cosibelimab-ipdl) has received a National Comprehensive Cancer Network® (NCCN®) Category 2A preferred designation for patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) who are not candidates for curative surgery or radiation. This designation is an addition to its existing Category 2A designation for metastatic CSCC. UNLOXCYT, approved by the U.S. FDA in 2024, is the first and only FDA-approved PD-L1-blocking antibody for advanced CSCC. The pivotal study showed a 55% objective response rate, with 26% complete responses, and durable responses. The drug also demonstrated a low incidence of high-grade immune-mediated adverse reactions.

Aeroflex Industries Limited has been granted an Indian patent for an innovative system and method to automatically generate 3D computer-aided models of braided hose assemblies. This patent underscores the company's commitment to R&D, engineering innovation, and automation. The technology aims to enhance design capabilities through data-driven innovation. Aeroflex, a manufacturer of flow control solutions, has a diverse product portfolio of over 3,300 SKUs and is expanding into high-potential segments like data centre liquid cooling. The company views R&D as crucial for its growth strategy and competitive positioning.

Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%. This generic drug is therapeutically equivalent to Sandoz Inc.'s Ciprodex Otic Suspension. The suspension is indicated for treating specific ear infections in pediatric, adult, and elderly patients. The estimated market size for this product was US$110 million for the twelve months ending June 2026. This approval adds to Alembic's portfolio, bringing their total USFDA ANDA approvals to 246.

Wanbury Limited announced significant progress in its API business. The company received 9 'No DMF Deficiency' letters from the USFDA for its Metformin HCl Drug Master File (DMF) during July-August 2026. Additionally, it received similar letters for Paroxetine and Diphenhydramine HCl, strengthening its position in the US market. Wanbury is expanding its API pipeline with new products like Quetiapine Fumarate, Sitagliptin, and Empagliflozin, planned for regulatory filings next quarter. The company is also growing its Metformin business, with new commercialization in Saudi Arabia (potential ₹10 crore annual revenue) and a two-year tender win in Mexico (valued at approximately ₹15 crore per annum). These developments underscore Wanbury's regulatory capabilities and growth prospects.

Neuland Laboratories Ltd has announced that the US FDA has issued an Establishment Inspection Report (EIR) for its Unit 3 manufacturing facility located in Gaddapotharam Village, Sangareddy District. The inspection, which took place from August 10 to August 14, 2026, has been concluded by the US FDA as 'closed'. This development pertains to the inspection conducted at their facility.

Dr Reddy's Laboratories Ltd announced that the United States Food and Drug Administration (USFDA) conducted a Pre-Approval Inspection (PAI) at its FTO-9 manufacturing facility in Visakhapatnam from October 8-9, 2026. The inspection resulted in the issuance of a Form 483 with three observations. The company stated it will address these observations within the stipulated timeline.